Literature DB >> 10508515

Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas.

S Laberge-le Couteulx1, H H Jung, P Labauge, J P Houtteville, C Lescoat, M Cecillon, E Marechal, A Joutel, J F Bach, E Tournier-Lasserve.   

Abstract

Cavernous angiomas are vascular malformations mostly located in the central nervous system and characterized by enlarged capillary cavities without intervening brain parenchyma. Clinical symptoms include seizures, haemorrhage and focal neurological deficits. Cavernous angiomas prevalence is close to 0.5% in the general population. They may be inherited as an autosomal dominant condition in as much as 50% of cases. Cerebral cavernous malformations (CCM) loci were previously identified on 7q, 7p and 3q (refs 4,5). A strong founder effect was observed in the Hispano-American population, all families being linked to CCM1 on 7q (refs 4,7). CCM1 locus assignment was refined to a 4-cM interval bracketed by D7S2410 and D7S689 (ref. 8). Here we report a physical and transcriptional map of this interval and that CCM1, a gene whose protein product, KRIT1, interacts with RAP1A (also known as KREV1; ref. 9), a member of the RAS family of GTPases, is mutated in CCM1 families. Our data suggest the involvement of the RAP1A signal transduction pathway in vasculogenesis or angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508515     DOI: 10.1038/13815

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  139 in total

Review 1.  Pathogenesis of hemangioma.

Authors:  D A Marchuk
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

2.  Krit1 missense mutations lead to splicing errors in cerebral cavernous malformation.

Authors:  Dominique J Verlaan; Adrian M Siegel; Guy A Rouleau
Journal:  Am J Hum Genet       Date:  2002-04-08       Impact factor: 11.025

3.  Phosphorylation sites in the cerebral cavernous malformations complex.

Authors:  Jaehong Kim; Nicholas E Sherman; Jay W Fox; Mark H Ginsberg
Journal:  J Cell Sci       Date:  2011-12-01       Impact factor: 5.285

Review 4.  Pathogenesis of vascular anomalies.

Authors:  Laurence M Boon; Fanny Ballieux; Miikka Vikkula
Journal:  Clin Plast Surg       Date:  2011-01       Impact factor: 2.017

Review 5.  Endogenous endothelial cell signaling systems maintain vascular stability.

Authors:  Nyall R London; Kevin J Whitehead; Dean Y Li
Journal:  Angiogenesis       Date:  2009-01-27       Impact factor: 9.596

Review 6.  Signaling pathways and the cerebral cavernous malformations proteins: lessons from structural biology.

Authors:  Oriana S Fisher; Titus J Boggon
Journal:  Cell Mol Life Sci       Date:  2013-11-29       Impact factor: 9.261

7.  pak2a mutations cause cerebral hemorrhage in redhead zebrafish.

Authors:  David A Buchner; Fengyun Su; Jennifer S Yamaoka; Makoto Kamei; Jordan A Shavit; Linda K Barthel; Beth McGee; Julio D Amigo; Seongcheol Kim; Andrew W Hanosh; Pudur Jagadeeswaran; Daniel Goldman; Nathan D Lawson; Pamela A Raymond; Brant M Weinstein; David Ginsburg; Susan E Lyons
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-22       Impact factor: 11.205

8.  ccm2-like is required for cardiovascular development as a novel component of the Heg-CCM pathway.

Authors:  Jonathan N Rosen; Vanessa M Sogah; Lillian Y Ye; John D Mably
Journal:  Dev Biol       Date:  2013-01-15       Impact factor: 3.582

Review 9.  Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling.

Authors:  Bryan T Richardson; Christopher F Dibble; Asya L Borikova; Gary L Johnson
Journal:  Biol Chem       Date:  2013-01       Impact factor: 3.915

10.  Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.

Authors:  Christopher C Gibson; Weiquan Zhu; Chadwick T Davis; Jay A Bowman-Kirigin; Aubrey C Chan; Jing Ling; Ashley E Walker; Luca Goitre; Simona Delle Monache; Saverio Francesco Retta; Yan-Ting E Shiu; Allie H Grossmann; Kirk R Thomas; Anthony J Donato; Lisa A Lesniewski; Kevin J Whitehead; Dean Y Li
Journal:  Circulation       Date:  2014-12-08       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.